Join to access to all OVN content. Join for Free
The Gamification of MSL Metrics
Gamifying MSL Metrics Medical Affairs Innovation MSL Performance Evaluation High-Impact Activities MSL Success Strategies

The Gamification of MSL Metrics


Share This Article


Summary

In this episode, Bart Brown joins Tom Caravela to explore the concept of gamifying MSL metrics. Bart shares his innovative point system designed to evaluate MSL performance beyond traditional metrics. They delve into the challenges of current evaluation methods and discuss how this new system emphasizes high-impact activities and diverse success strategies. Bart provides insights on implementing these strategies and addresses potential downsides. The conversation highlights the importance of showcasing value in Medical Affairs. The episode wraps up with a call for listener feedback and suggestions for future topics.

My guest this week is Bart Brown, Medical Affairs Leader who shares his interesting concept on how to gamify MSL metrics and KPIs.

Bart shares….

πŸ‘‰ How are MSLs currently evaluated and what is the standard
πŸ‘‰ A unique way to “gamify” MSL metrics and KPIs
πŸ‘‰ How this unique system can be implemented and why
πŸ‘‰ What the benefits would be to this system
πŸ‘‰ What advice he has for MSL success in 2024

Click for Source
Gamifying MSL Metrics, Medical Affairs Innovation, MSL Performance Evaluation, High-Impact Activities, MSL Success Strategies

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN